According to DPI developer Iconovo, the company has now signed a strategic collaboration deal with CDMO Lonza for development of spray dried formulation of inhaled biologics. In January 2025, Iconovo said that Lonza would develop spray dried dry powder formulations of an obesity drug for delivery by Iconovo’s ICOone nasal device. Earlier this year, the companies signed a letter of intent as an initial step toward a collaboration.
Iconovo CEO Anders Månsson commented, “The parties have so far reached the signing of a strategic collaboration agreement . . . . The currently signed agreement will serve as an umbrella agreement for project specific collaborations, which are projected to be added in the near-term future.”
Lonza VP, Commercial Development, Advanced Synthesis, Jan Vertommen said, “We consider inhalable biologics utilizing our spray drying technologies and expertise to be areas of great interest, and we look forward to extending our collaboration with Iconovo.”
Read the Iconovo press release
